D. Boral Capital reissued their buy rating on shares of Can-Fite BioPharma (NYSE:CANF – Free Report) in a research report sent to investors on Tuesday,Benzinga reports. D. Boral Capital currently has a $10.00 price target on the stock.
Separately, StockNews.com began coverage on Can-Fite BioPharma in a research report on Saturday. They issued a “sell” rating on the stock.
View Our Latest Research Report on CANF
Can-Fite BioPharma Price Performance
Institutional Inflows and Outflows
A hedge fund recently raised its stake in Can-Fite BioPharma stock. Rhumbline Advisers boosted its position in shares of Can-Fite BioPharma Ltd. (NYSE:CANF – Free Report) by 58.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 26,880 shares of the company’s stock after buying an additional 9,935 shares during the period. Rhumbline Advisers owned 0.76% of Can-Fite BioPharma worth $44,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 21.00% of the company’s stock.
About Can-Fite BioPharma
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.
Featured Stories
- Five stocks we like better than Can-Fite BioPharma
- What does consumer price index measure?
- Arqit Stock Soars as NVIDIA’s GTC Fuels Quantum Excitement
- Breakout Stocks: What They Are and How to Identify Them
- 3 Must-Own Stocks to Build Wealth This Decade
- How to start investing in penny stocks
- Advanced Micro Devices Eyes AI Market Growth—Is AMD a Buy?
Receive News & Ratings for Can-Fite BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Can-Fite BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.